Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Feb 20;22(2):167-168.
doi: 10.1093/neuonc/noz224.

Salinomycin targets the genome of radioresistant cells in glioblastomas

Steven L Carroll  1 , Jody Fromm Longo  1
Affiliations
Comment

Salinomycin targets the genome of radioresistant cells in glioblastomas

Steven L Carroll et al. Neuro Oncol. .
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The many functions of salinomycin. Chemical structure of salinomycin surrounded several of the regulatory biological functions it regulates. Previously reported activities of salinomycin are displayed in black, while activities newly identified by Lim et al are in red.
See this image and copyright information in PMC

Comment on

References

    1. Jeggo PA, Pearl LH, Carr AM. DNA repair, genome stability and cancer: a historical perspective. Nat Rev Cancer. 2016;16(1):35–42. - PubMed
    1. Knijnenburg TA, Wang L, Zimmermann MT, et al. Genomic and molecular landscape of DNA damage repair deficiency across the cancer genome atlas. Cell Rep. 2018;23(1):239–254 e236. - PMC - PubMed
    1. Gavande NS, VanderVere-Carozza PS, Hinshaw HD, et al. DNA repair targeted therapy: the past or future of cancer treatment? Pharmacol Ther. 2016;160:65–83. - PMC - PubMed
    1. Stupp R, Hegi ME, Mason WP, et al. ; European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10(5):459–466. - PubMed
    1. Gil Del Alcazar CR, Todorova PK, Habib AA, Mukherjee B, Burma S. Augmented HR repair mediates acquired temozolomide resistance in glioblastoma. Mol Cancer Res. 2016;14(10):928–940. - PMC - PubMed